Hypera S.A.

BOVESPA:HYPE3 주식 보고서

시가총액: R$13.0b

Hypera 과거 수익 실적

과거 기준 확인 2/6

Hypera은 연평균 8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 6.2%였습니다. 매출은 연평균 19.2%의 비율로 증가했습니다. Hypera의 자기자본이익률은 12.8%이고 순이익률은 20.2%입니다.

주요 정보

8.0%

수익 성장률

7.9%

EPS 성장률

Pharmaceuticals 산업 성장12.4%
매출 성장률19.2%
자기자본 수익률12.8%
순이익20.2%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

Nov 21
More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Nov 14
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

Oct 03
Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Jul 13
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Jun 20
Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16
Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Is Hypera (BVMF:HYPE3) A Risky Investment?

Feb 21
Is Hypera (BVMF:HYPE3) A Risky Investment?

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Jan 09
Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Dec 22
Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Nov 02
Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Aug 27
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Is Hypera (BVMF:HYPE3) A Risky Investment?

Jul 21
Is Hypera (BVMF:HYPE3) A Risky Investment?

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Apr 15
We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Feb 19
With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Jan 03
We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Oct 11
Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Jul 19
Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Jun 28
Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Apr 14
Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Mar 25
I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Mar 04
Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

수익 및 비용 분석

Hypera 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

BOVESPA:HYPE3 수익, 비용 및 수입 (BRL Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 247,7781,5702,5480
30 Jun 248,0011,6932,5070
31 Mar 248,0431,7042,5110
31 Dec 237,9151,6492,5210
30 Sep 238,1891,7722,5310
30 Jun 238,0861,7412,4920
31 Mar 237,7511,6942,3750
31 Dec 227,5461,7052,2990
30 Sep 227,0511,6402,1210
30 Jun 226,6481,6362,0170
31 Mar 226,2601,6601,9550
31 Dec 215,9371,6181,8950
30 Sep 215,4461,5771,8720
30 Jun 214,9021,4621,7560
31 Mar 214,4451,3821,6260
31 Dec 204,0891,3221,5640
30 Sep 203,8831,2431,5380
30 Jun 203,8031,1651,6050
31 Mar 203,7261,1061,6350
31 Dec 193,2951,1891,6110
30 Sep 193,2941,2521,5580
30 Jun 193,2331,2251,5080
31 Mar 193,1801,1641,4690
31 Dec 183,7241,1351,4810
30 Sep 183,7891,2881,5080
30 Jun 183,7161,2511,4770
31 Mar 183,6131,2001,4300
31 Dec 173,5001,1111,4100
30 Sep 173,2918191,3970
30 Jun 173,2267951,3800
31 Mar 173,2167431,3940
31 Dec 163,2286471,3720
30 Sep 163,2025571,3600
30 Jun 163,1294321,3390
31 Mar 163,0463491,3230
31 Dec 152,9573451,3070
30 Sep 151,5892637740
30 Jun 152,0393269440
31 Mar 152,4473601,0950
31 Dec 142,7683381,2450
30 Sep 144,4984001,9130
30 Jun 144,4233571,8630
31 Mar 144,3592491,8510
31 Dec 134,2592591,8040

양질의 수익: HYPE3 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: HYPE3 의 현재 순이익 이익률 (20.2%) 작년보다 낮습니다 (21.6%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: HYPE3 의 수입은 지난 5년 동안 매년 8% 씩 증가했습니다.

성장 가속화: HYPE3 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: HYPE3 은 지난 1년 동안 마이너스 수익 성장( -11.4% )을 기록하여 Pharmaceuticals 업계 평균( 8.5% ).


자기자본 수익률

높은 ROE: HYPE3 의 자본 수익률( 12.8% )은 낮음으로 간주됩니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기